www.nanochipxl.com Infection Control Panel SCREEN, ISOLATE, PROTECT Savyon Diagnostics is now offering its revolutionary test panel for the detection of MRSA, VRE and KPC directly from swab samples using the NanoChip ® XL molecular microarray system, thus enabling medium-high throughput screening from sample to results on the same working day and with minimal hands-on time. MRSA, VRE, KPC
2
Embed
Infection Control Panel - Clindia Beneluxnedcon.clindia.nl/_files/Brochures/Savyon/ICP-Brochure.pdf · Infection Control Panel SCREEN, ISOLATE, PROTECT Savyon Diagnostics is now offering
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
www.nanochipxl.com
Infection Control PanelSCREEN, ISOLATE, PROTECT
Savyon Diagnostics is now offering its revolutionary test panel for the detection of MRSA, VRE and KPC directly from swab samples using the NanoChip®XL molecular microarray system, thus enabling medium-high throughput screening from sample to results on the same working day and with minimal hands-on time.
NanoChip is a registered trademarks of Gamida B.V, The Netherlands.The cartridge and NanoChip 400 system and their use may be covered by one or more of following U.S. Patents or Applications: 5,605,662; 5,929,208; 6,017,696; 6,238,624; 5,632,957; 6,582,660; 5,849,486; 6,245,508; 6,048,690; 6,051,380; 6,518,022; 2003/0190632; 5,965,452; 6,258,606; 6,682,936; 6,687,048; 2002/0131899A1; 2004/0149582A1; 6,099,803; 6,726,880; 6,225,059; 6,068,818; 6,540,961; 6,254,827; 6,315,953; 6,821,729; 6,331,274; US-2004-0038420-A1; 6,306,348; 6,524,517; 6,303,082; 6,838,053; 2005/0158451A1; 6,960,298; 2005/0164283A1; 6,207,373; 6,395,493; 6,753,148; 6,468,742; 2003/0073122; 6,379,897; 6,492,122.
Please note: Purchase of this instrument conveys a limited non-transferable immunity from suit for the purchaser›s own human in vitro diagnostics other than internal research and development and applied fields under non-real-time thermal cycler patents of Applied Biosystems LLC
Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE) and Carbapenemase producing Klebsiella pneumoniae (KPC) colonization in hospital admitted patients is the leading cause for Hospital Acquired Infections (HAI). It is now evident that HAI can be widely prevented through screening of patients before or during hospital admission and proper patient isolation and management.
Molecular Targets
# Pathogen Gene Relevance
1 S. aureus spa & nuc
Detect & differentiate between S.aureus and other staphylococcal strains. (complementary markers)